Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials

References

• Bartlett JG, Breiman RF, Mandell LA, File Jr. TH. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811–38
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820–37
   Google Scholar
• Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618–24
   PubMed Web of Science ®Google Scholar
• Marston BJ, Plouffe JF, File Jr. TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997;157:1709–18
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–54
   Google Scholar
• Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985;78(Suppl 6B):45–51
   Google Scholar
• Birnbaum HG, Morley M, Greenberg PE, Colice GL. Economic burden of respiratory tract infections in an employed population. Chest 2002;122:603–11
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Infectious Diseases Society of America. Clin Infect Dis 2003;37:1405–33
   Google Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399–408
   PubMed Web of Science ®Google Scholar
• Felmingham D, Grüneberg RN, and the Alexander Project Group. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45: 191–203
   Google Scholar
• Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. J Infect 2002;44(Suppl A): 3–10
   Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229–46
   PubMed Web of Science ®Google Scholar
• Lorenz J. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired infections. Int J Clin Pract 2003;57:519–29
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs 2002;62:1771–804
   PubMed Web of Science ®Google Scholar
• Fogarty C, Patel TC, Galbraith H, Zuberbuhler GA, Leroy B. Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of adult patients with community-acquired pneumonia caused by Streptococcus pneumoniae [Abstract 857]. In: Abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, September 22–25, 2001, Chicago, USA. Washington, DC: American Society for Microbiology; 2001. p. 449
   Google Scholar
• Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30:378–86
   PubMed Web of Science ®Google Scholar
• van Rensburg DJ, Matthews PA, Leroy B. Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Opin Med Res 2002;18:397–400
   PubMed Web of Science ®Google Scholar
• Pullman J, Champlin J, Vrooman PS. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003;57:377–84
   Google Scholar
• Carbon C, Moola S, Velancsics I, Leroy B, Rangaraju M, Decosta P. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect 2003;9:691–703
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48–62
   Google Scholar
• Tellier G, Isakov T, Peterman W, Patel M, Lavin B. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia [Abstract L-373]. In: Abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, September 27–30, 2002, San Diego, USA. Washington, DC: American Society for Microbiology; 2002. p. 346
   Google Scholar
• Niederman MS, Chang JR, Stewart J, Nusrat N, Nieman RB. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10-days of telithromycin or clarithromycin. Curr Med Res Opin 2004;20: 749–56
   Google Scholar
• Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7days or clarithromycin for 10 days. Curr Med Res Opin 2004;20:739–47
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243–50
   PubMed Web of Science ®Google Scholar
• American Hospital Association. Hospital statistics, 2002 ed. Chicago: Health Forum, an American Hospital Association affiliate; 2003. p. 4
   Google Scholar
• Fleiss JL. Statistical methods for rates and proportions, 2nd ed. New York: John Wiley and Sons, Inc; 1981. p. 100–11
   Google Scholar
• Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096–121
   Web of Science ®Google Scholar
• Chang JR, Stewart J, Cadilhac M, Nieman RB. Telithromycin (TEL) results in fewer hospitalizations than amoxicillin–clavulanate (AMC) in the outpatient treatment of acute exacerbations of chronic bronchitis (AECB). Value Health 2003;6:250–1
   Web of Science ®Google Scholar
• Mandell L, Chang J, Oster G, et al. Comparison of healthcare utilization in patients with acute exacerbations of chronic bronchitis (AECB) receiving telithromycin (TEL) versus clarithromycin (CLA) in a randomized, double-blind, multicenter clinical trial [Abstract L1595]. In: Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, September 14–17, 2003, Chicago, USA. Washington, DC: American Society for Microbiology; 2003. p. 428
   Google Scholar
• Odenholt L, Löwdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001;45:23–9
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Pharmacodynamic rationale for short-duration antibacterial therapy. J Infect 2002;44 (Suppl A):17–23
   Google Scholar
• Norrby SR, Chang J, Stewart JA, Brumpt I, Conway DP. Relief of symptoms in patients with group A β-hemolytic streptococcus tonsillopharyngitis: comparison between telithromycin and penicillin V. Scand J Infect Dis 2003;35:223–5
   Google Scholar